===
Sartorius Stedim Biotech SA / Key word(s): Miscellaneous
Sartorius Stedim Biotech Capital Markets: Links to presentation and webcast
17-May-2024 / 19:32 CET/CEST
Aubagne, France | May 17, 2024


Sartorius Stedim Biotech Capital Markets: Links to presentation and webcast

Sartorius Stedim Biotech held its Capital Markets Day (CMD) yesterday presenting its business strategy and goals. The
company explained and confirmed its forecast for 2024 and the medium-term ambition up to 2028. In order to ensure broad
access to the CMD presentation, which has been published on the company's website since the start of the CMD, we hereby
refer to the corresponding link. We are also providing the link to the webcast.

Capital Markets Day Presentation
Webcast


Financial calendar
July 19, 2024 Publication of the first-half figures (January to June 2024)
October 17, 2024 Publication of the nine-month figures (January to September 2024)

A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of
innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications,
such as cell and gene therapies, safely, rapidly, and economically. The shares of Sartorius Stedim Biotech S.A. are
quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales
entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through
acquisitions of complementary technologies. In 2023, the company generated sales revenue of around 2.8 billion euros.
By the end of 2023, more than 10,600 employees were working for customers around the globe.

Visit our newsroom and follow Sartorius Stedim Biotech on LinkedIn.


Contact
Petra Kirchhoff
Head of Corporate Communications & Investor Relations
+49 (0)551 308 1686
petra.kirchhoff@sartorius.com
Dissemination of a Financial Wire News, transmitted by EQS Group.

The issuer is solely responsible for the content of this announcement.  
Language:     English 
Issuer:       Sartorius Stedim Biotech SA 

Avenue de Jouques
13781 Aubagne
France

Phone:        +33 44 284 5600 
E-mail:       sartorius.presse@sartorius.com 
Internet:     www.sartorius-stedim.com 
ISIN:         FR0013154002 
EQS News ID:  1906303 

End of Announcement - EQS News Service
===
1906303 17-May-2024 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1906303&application_name=news

END) Dow Jones Newswires

May 17, 2024 13:32 ET (17:32 GMT)